{
    "data": [
        {
            "id": "4564828",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-15T21:51:42-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365433909/image_1365433909.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: Time To Revisit And It's A 'Buy'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "426194",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564828-chemours-stock-revisit-buy"
            }
        },
        {
            "id": "4544600",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-04T11:10:05-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393468721/image_1393468721.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Company: No Discount For This Cyclical Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "77115",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "412517",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544600-chemours-company-no-discount-for-this-cyclical-stock"
            }
        },
        {
            "id": "4544238",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-02T05:52:58-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365442737/image_1365442737.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: The Wrong Call Before, But Now A 'Buy'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "412068",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544238-chemours-the-wrong-call-before-but-now-a-buy"
            }
        },
        {
            "id": "4524618",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-20T23:41:32-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296203490/image_1296203490.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Company - 'Hold' Was The Right Call - Moving To 'Buy'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "383596",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524618-chemours-company-stock-hold-was-the-right-call-moving-to-buy"
            }
        },
        {
            "id": "4507076",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-04T23:08:29-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365442738/image_1365442738.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: A Drop Followed By A Massive Bounce, Upside Still Uncertain",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "372501",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4507076-chemours-q1-2022-earnings-upside-still-uncertain"
            }
        },
        {
            "id": "4486769",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-14T08:22:47-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365442738/image_1365442738.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: 15% Still Isn't Enough - But Look At Options",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361479",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486769-chemours-15-percent-still-isnt-enough-but-look-at-options"
            }
        }
    ]
}